This SensoLyte® high-sensitivity (2 pg/ml) beta-Amyloid (1-42) Quantitative ELISA Kit (Human) provides a convenient and quantitative assay for determining human beta-Amyloid (1-42) (Aβ42) amount in cell and tissue lysate as well as in body fluids. Compared to other anti-human Aβ42 ELISA kits on the market, it takes less time to run this assay. HRP conjugated detection antibody in this kit is added simultaneously with samples and standards during the assay. This eliminates extra incubation and washing steps and makes this kit one-step procedure for Aβ42 quantification. Alzheimer’s Disease (AD) is the most common neurodegenerative disorder in elderly people. It has been demonstrated that AD has biological cause and is characterized by the presence of senile plaques and neurofibrillary tangles mainly in cerebral cortex and hippocampus brain regions (1-5). Beta-Amyloid (1-40) (Aβ40) and beta-Amyloid (1-42) (Aβ42) are the main components of the above plaques; however, other forms of beta-Amyloid peptides are also present. Both peptides are cleaved from the Amyloid Precursor Protein (APP) by β-secretase and γ-secretase enzymes (2,3,5).Many studies suggest that Aβ42 or/and Aβ43 are required to initiate formation of amyloid plaques and neurofibrills that leads to the neurodegeneration (1-5); while Aβ40 is less neurotoxic. Recently, increased levels of beta-Amyloid (1-42) peptide in human saliva were identified in mild Alzheimer’s disease patients (6). It may be possible to use saliva level of beta-Amyloid peptides to assess higher risk of acquiring Alzheimer’s disease in the future or to monitor disease progress.

Figure 1. An example of the human Aβ-42 ELISA standard curve.